FY2019 Earnings Forecast for Xencor Inc Issued By Cantor Fitzgerald (XNCR)
Xencor Inc (NASDAQ:XNCR) – Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for Xencor in a research note issued on Monday. Cantor Fitzgerald analyst W. Tanner expects that the biopharmaceutical company will earn ($2.12) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $33.00 target price on the stock.
A number of other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Xencor from a “sell” rating to a “strong sell” rating in a research report on Friday, December 15th. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price objective on shares of Xencor in a research report on Sunday, November 12th. ValuEngine lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the company a “buy” rating in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. Xencor has an average rating of “Hold” and a consensus target price of $30.80.
A number of institutional investors have recently added to or reduced their stakes in XNCR. FMR LLC lifted its holdings in Xencor by 77.7% in the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after acquiring an additional 2,924,510 shares during the period. State Street Corp lifted its holdings in Xencor by 11.1% in the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after acquiring an additional 110,474 shares during the period. Artal Group S.A. acquired a new stake in Xencor in the third quarter valued at $2,292,000. JPMorgan Chase & Co. lifted its holdings in Xencor by 48.1% in the second quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after acquiring an additional 93,975 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Xencor by 5.6% in the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after acquiring an additional 90,094 shares during the period. 77.50% of the stock is owned by institutional investors.
In other Xencor news, major shareholder John S. Stafford III bought 50,000 shares of Xencor stock in a transaction on Thursday, November 2nd. The stock was bought at an average price of $19.58 per share, with a total value of $979,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III bought 24,653 shares of Xencor stock in a transaction on Wednesday, October 25th. The stock was acquired at an average cost of $20.01 per share, with a total value of $493,306.53. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 278,535 shares of company stock worth $5,526,936. 4.03% of the stock is currently owned by insiders.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/04/fy2019-earnings-forecast-for-xencor-inc-issued-by-cantor-fitzgerald-xncr.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.